Discover the power of Jivi
EHL rFVIIIs are not the same: The difference is Jivi
Jivi’s powerful protection can be
individualised to your patient’s unique needs
Whether your patient is a teenager who wants to keep up with his friends, someone struggling with joint pain, or even an older patient with age-related comorbidities, Jivi’s powerful protection can be individualised to their unique needs.
See how Jivi can help your patients get more out of life
* Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing. In non-EU countries other FVIII treatments may have previously launched – or are currently available – which also offer 1x weekly dosing.
† Based on head-to-head studies comparing the pharmacokinetic profiles of Jivi vs. rFVIII-Fc and Jivi vs. rurioctocog alfa pegol
‡ At extension completion, patients received Jivi for a median (range) total time of 3.9 (0.8–7.0) years with 223 (23–698) exposure days
References
- Jivi Summary of Product Characteristics. Return to content
- Reding MT et al. Haemophilia 2021; 00: 1–10. Return to content
- Reding MT et al. Haemophilia 2020;26:e201–e204. Return to content
- Shah A et al. Ann Hematol 2019; 98(9): 2035-2044. Return to content
- Reading MT et al. J Thromb Haemost 2017; 15: 411-419. Return to content
- Lalezari S et al. Haemophilia. 2019; 25: 1011-1019 Return to content
- Solms A, et al. Ann Hematol 2020; 99, 2689–2698 Return to content
- Berntorp E et al. Blood Rev; 2021: https://doi.org/10.1016/j.blre.2021.100852 (epub ahead of print). Return to content
